Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Sep 8;22(9):1505. doi: 10.3390/molecules22091505

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2017 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Effects of RGO and its major components on hair follicle development in the TES-induced androgenic alopecia C57BL/6 mouse models. The shaved-back skins of mice were treated with 0.5% TES for 1 h prior to topical application of 10% RGO, 1% LA, 1% SITOS, or 1% BICYCLO once a day for 28 days. Mice in the positive control group were treated with 0.5% TES and orally administered with FINAS (1 mg/kg) once a day for 28 days. The dorsal skin tissues of each group were collected at day 17 after treatment and subjected to hematoxylin and eosin (H&E) staining. (A) Representative photomicrographs of longitudinal sections are shown. Magnification ×40 (upper panel) and ×100 (lower panel); (B) Hair growth pattern (anagen/telogen ratio) in C57BL/6 mice. Data are presented as the mean ± SD of three independent experiments. ^# p < 0.05 significant difference as compared with vehicle-treated control group. * p < 0.05 significant difference as compared with TES-treated group.

Effects of RGO and its major components on hair follicle development in the TES-induced androgenic alopecia C57BL/6 mouse models. The shaved-back skins of mice were treated with 0.5% TES for 1 h prior to topical application of 10% RGO, 1% LA, 1% SITOS, or 1% BICYCLO once a day for 28 days. Mice in the positive control group were treated with 0.5% TES and orally administered with FINAS (1 mg/kg) once a day for 28 days. The dorsal skin tissues of each group were collected at day 17 after treatment and subjected to hematoxylin and eosin (H&E) staining. (A) Representative photomicrographs of longitudinal sections are shown. Magnification ×40 (upper panel) and ×100 (lower panel); (B) Hair growth pattern (anagen/telogen ratio) in C57BL/6 mice. Data are presented as the mean ± SD of three independent experiments. ^# p < 0.05 significant difference as compared with vehicle-treated control group. * p < 0.05 significant difference as compared with TES-treated group.